Mechanisms of acquired resistance to AKT inhibitor capivasertib in AKT1 mutant patient derived breast cancer models

被引：0
|
作者：
Mearns, Sarah
Pearson, Alex
Sim, Li-Xuan
Cutts, Rosalind
Sritharan, Prithika
Shah, Heena
Gulati, Aditi
Williamson, Stuart
Barry, Simon
De-Bruin, Elza
Turner, Nicholas C.
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-LB450
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB450
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Proximity ligation assays for isoform-specific Akt activation in breast cancer identify activated Akt1 as a driver of progression
    Spears, Melanie
    Cunningham, Carrie A.
    Taylor, Karen J.
    Mallon, Elizabeth A.
    Thomas, Jeremy St J.
    Kerr, Gillian R.
    Jack, Wilma J. L.
    Kunkler, Ian H.
    Cameron, David A.
    Chetty, Udi
    Bartlett, John M. S.
    JOURNAL OF PATHOLOGY, 2012, 227 (04): : 481 - 489
  • [32] Molecular characterization of anastrozole resistance in breast cancer: Pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor
    Vilquin, Paul
    Villedieu, Marie
    Grisard, Evelyne
    Ben Larbi, Sabrina
    Ghayad, Sandra E.
    Heudel, Pierre-Etienne
    Bachelot, Thomas
    Corbo, Laura
    Treilleux, Isabelle
    Vendrell, Julie A.
    Cohen, Pascale A.
    INTERNATIONAL JOURNAL OF CANCER, 2013, 133 (07) : 1589 - 1602
  • [33] Capivasertib: A Novel AKT Inhibitor Approved for Hormone-Receptor-Positive, HER-2-Negative Metastatic Breast Cancer
    Luboff, Alexa J.
    DeRemer, David L.
    ANNALS OF PHARMACOTHERAPY, 2024, 58 (12) : 1229 - 1237
  • [34] Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models (vol 9, 64, 2023)
    Hopcroft, Lorna
    Wigmore, Eleanor M.
    Williamson, Stuart C.
    Ros, Susana
    Eberlein, Cath
    Moss, Jennifer I.
    Urosevic, Jelena
    Carnevalli, Larissa S.
    Talbot, Sara
    Bradshaw, Lauren
    Blaker, Catherine
    Gunda, Sreeharsha
    Owenson, Venetia
    Hoffmann, Scott
    Sutton, Daniel
    Jones, Stewart
    Goodwin, Richard J. A.
    Willis, Brandon S.
    Rooney, Claire
    de Bruin, Elza C.
    Barry, Simon T.
    NPJ BREAST CANCER, 2023, 9 (01)
  • [35] Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer
    ter Brugge, Petra
    Kristel, Petra
    van der Burg, Eline
    Boon, Ute
    de Maaker, Michiel
    Lips, Esther
    Mulder, Lennart
    de Ruiter, Julian
    Moutinho, Catia
    Gevensleben, Heidrun
    Marangoni, Elisabetta
    Majewski, Ian
    Jozwiak, Katarzyna
    Kloosterman, Wigard
    van Roosmalen, Markus
    Duran, Karen
    Hogervorst, Frans
    Turner, Nick
    Esteller, Manel
    Cuppen, Edwin
    Wesseling, Jelle
    Jonkers, Jos
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2016, 108 (11):
  • [36] Unveiling mechanisms of CDK4/6 inhibitor resistance in ER plus breast cancer models with acquired resistance
    Li, Bin
    Liu, Gaoxiang
    Ni, Ting
    Shi, Wenting
    Gu, Qingyang
    CANCER RESEARCH, 2024, 84 (06)
  • [37] Evaluation of p70S6K/Akt inhibitor MSC2363318A in patient derived xenograft (PDX) models of breast cancer
    Huck, Bayard R.
    Tian, H.
    Syed, Sakeena
    Lin, Jing
    Ma, Jianguo
    Clark, Anderson
    Kaleta, Remiguisz
    Machl, Andreas
    Wilker, Erik
    Lecomte, Marc
    CANCER RESEARCH, 2014, 74 (19)
  • [38] AKT1 regulates UHRF1 protein stability and promotes the resistance to abiraterone in prostate cancer
    Fu, Yongming
    Cao, Tuoyu
    Zou, Xiaorui
    Ye, Yubing
    Liu, Youhong
    Peng, Yuchong
    Deng, Tanggang
    Yin, Linglong
    Li, Xiong
    ONCOGENESIS, 2023, 12 (01)
  • [39] AKT1 regulates UHRF1 protein stability and promotes the resistance to abiraterone in prostate cancer
    Yongming Fu
    Tuoyu Cao
    Xiaorui Zou
    Yubing Ye
    Youhong Liu
    Yuchong Peng
    Tanggang Deng
    Linglong Yin
    Xiong Li
    Oncogenesis, 12
  • [40] Activity and tolerability of combination of trastuzumab deruxtecan with the pan-AKT inhibitor capivasertib in preclinical HER2+and HER2-low breast cancer models
    Bashi, Azadeh Cheraghchi
    Proia, Theresa
    Randle, Suzanne
    Anderton, Mark
    Rasheed, Zeshaan
    Pease, J. Elizabeth
    Barry, Simon
    Carroll, Danielle
    Mettetal, Jerome
    CANCER RESEARCH, 2022, 82 (04)
12345